Patents by Inventor Jaspal Singh Kang
Jaspal Singh Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235062Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: ApplicationFiled: November 1, 2022Publication date: July 27, 2023Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOOK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
-
Patent number: 11518809Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: July 23, 2019Date of Patent: December 6, 2022Assignee: MEDIMMUNE LIMITEDInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Patent number: 11492411Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 4, 2019Date of Patent: November 8, 2022Assignee: Amgen Fremont Inc.Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20210017282Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: ApplicationFiled: July 23, 2019Publication date: January 21, 2021Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
-
Publication number: 20200062860Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 4, 2019Publication date: February 27, 2020Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R.F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 10563206Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.Type: GrantFiled: January 24, 2019Date of Patent: February 18, 2020Assignee: INNOVATIVE TARGETING SOLUTIONS INC.Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Patent number: 10508153Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 18, 2015Date of Patent: December 17, 2019Assignee: Amgen Fremont Inc.Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20190359937Abstract: A receptor is provided having a heterologous binding site that activates, when bound, a signaling domain related to the TNF receptor superfamily. Methods/uses of the foregoing in whole cell biosensors are also provided. There is also provided a library comprising a plurality of unique biosensor cells for binding unknown binding substrates. Each unique biosensor is a host cell having a receptor which signals production of a positive selectable marker and/or a negative selectable marker in response to the receptor being bound. Also provided is a method of identifying biosensor cells from a library that is specifically activated by a target, involving (a) contacting the library with the target substrate under positive selection conditions; (b) contacting the library with a control substrate under negative selection conditions; and (c) identifying biosensor cells which survive (a) and (b) as biosensor cells which are specifically activated by the target.Type: ApplicationFiled: November 17, 2017Publication date: November 28, 2019Applicant: Innovative Targeting Solutions Inc.Inventors: Craig Robin Pigott, Michael Lajos Gallo, Jaspal Singh Kang
-
Patent number: 10400039Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: October 25, 2016Date of Patent: September 3, 2019Assignee: MEDIMMUNE LIMITEDInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Publication number: 20190255186Abstract: There is provided a single variable domain T-cell receptor (svd-TCR) comprising a first TCR variable domain, the first TCR variable domain specifically binding to an epitope, that is not a superantigen, in the absence of a second TCR variable domain. Also provided are compositions and cells comprising the svd-TCR as well as methods of identifying the svd-TCR.Type: ApplicationFiled: December 2, 2016Publication date: August 22, 2019Inventors: Michael Lajos GALLO, Jaspal Singh KANG, Craig Robin PIGOTT, Abby LIN, Falene CHAI
-
Publication number: 20190144872Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.Type: ApplicationFiled: January 24, 2019Publication date: May 16, 2019Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Patent number: 10233453Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.Type: GrantFiled: November 2, 2017Date of Patent: March 19, 2019Assignee: INNOVATIVE TARGETING SOLUTIONSInventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Publication number: 20180119155Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.Type: ApplicationFiled: November 2, 2017Publication date: May 3, 2018Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Patent number: 9914929Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.Type: GrantFiled: March 14, 2013Date of Patent: March 13, 2018Assignee: Innovative Targeting Solutions Inc.Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Publication number: 20170334970Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.Type: ApplicationFiled: May 1, 2017Publication date: November 23, 2017Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby Lin
-
Patent number: 9718871Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.Type: GrantFiled: March 14, 2013Date of Patent: August 1, 2017Assignee: INNOVATIVE TARGETING SOLUTIONS INC.Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby Lin
-
Publication number: 20170137522Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: ApplicationFiled: October 25, 2016Publication date: May 18, 2017Applicant: MEDIMMUNE LIMITEDInventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
-
Patent number: 9493565Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: May 6, 2014Date of Patent: November 15, 2016Assignee: MedImmune LimitedInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
-
Publication number: 20160297883Abstract: Peptide-grafted antibodies having agonist activity against a Class B GPCR and their uses, and methods for identifying same. Mammalian cell lines for high-throughput screening for agonists of a Class B GPCR are also provided that comprise a stably integrated recombinant nucleic acid construct comprising a reporter gene under control of a cAMP responsive promoter, the reporter gene encoding a cell surface expressed protein, and a stably integrated recombinant nucleic acid construct comprising a sequence encoding a Class B GPCR under control of a constitutive promoter.Type: ApplicationFiled: December 4, 2014Publication date: October 13, 2016Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby YU Chen Lin
-
Publication number: 20150329850Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.Type: ApplicationFiled: March 14, 2013Publication date: November 19, 2015Inventors: Michael Gallo, Jaspal Singh KANG, Craig Robin Pigott, Abby Lin